Literature DB >> 2854599

VSV G protein induces murine cytolytic T lymphocytes.

C S Reiss1, S S Chen, A S Huang, R Doherty.   

Abstract

Mice immunized with vesicular stomatitis virus (VSV), with its glycoprotein (G) in lipid vesicles or with a truncated, soluble form of G called Gs, developed an expanded population of virus specific cytolytic T lymphocyte (CTL) precursors and also led to the production of neutralizing serum antibody. The CTL precursors could be restimulated in vitro with either the virus or its glycoprotein components. Thus the glycoprotein of VSV, either associated with lipids or in soluble form, induced both cellular and humoral immune responses that might be sufficient to result in protective immunity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2854599     DOI: 10.1016/0882-4010(86)90050-1

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  5 in total

1.  The soluble viral glycoprotein of vesicular stomatitis virus efficiently sensitizes target cells for lysis by CD4+ T lymphocytes.

Authors:  M Browning; C S Reiss; A S Huang
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

2.  Cytokine-modified VSV is attenuated for neural pathology, but is both highly immunogenic and oncolytic.

Authors:  James Miller; Sarah M Bidula; Troels M Jensen; Carol Shoshkes Reiss
Journal:  Int J Interferon Cytokine Mediat Res       Date:  2009-12-01

3.  Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice.

Authors:  B S Huneycutt; Z Bi; C J Aoki; C S Reiss
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

4.  Murine infection by vesicular stomatitis virus: initial characterization of the H-2d system.

Authors:  J M Forger; R T Bronson; A S Huang; C S Reiss
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

5.  Processing of a viral glycoprotein in the endoplasmic reticulum for class II presentation.

Authors:  S M Bartido; S Diment; C S Reiss
Journal:  Eur J Immunol       Date:  1995-08       Impact factor: 5.532

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.